Western medicine is not running smoothly [1] [2] [3] . In this paper we summarise the state of affairs in Europe. In Focus
Phages are medicinal products
In the European Union (EU), the rediscovered phage preparations were classified as 'Medicinal Products' -'Drugs' in the United States (US) 4 . The second one is the clinical phase II Phagoburn trial (http://www.phagoburn.eu), designed to evaluate the treatment of P. aeruginosa and Escherichia coli infected burn wounds using two dedicated phage cocktails 10 . Cocktails of no less than 12 and 13 phages were needed to ensure a certain activity against pre-defined collections of P. aeruginosa and E. coli isolates, respectively. Manufacturing of one batch (according to GMP) of the investigational PTMPs took 20 months and the largest part of the study budget and only a very small number of phages (10-100 PFU/mL instead of the anticipated 10 6 PFU/mL) was actually applied due to stability problems of the phage cocktails.
In addition, phage specificity issues hampered the recruitment of patients. Because each of the two study products, which couldn't be applied simultaneously, targeted only one of the multiple bacterial species that are known to (simultaneously) infect or colonise burn wounds, physicians were reluctant to include patients 11 . Only 27 patients were enrolled in the P. aeruginosa arm of the study and the E. coli arm was stopped (only one patient was enrolled). At very low concentrations, the P. aeruginosa phage cocktail was shown to decrease the bacterial load in burn wounds, but at a slower pace than the standard of care (silver sulfadiazine cream). Further studies using higher phage concentrations and selected phage preparations, taking into account the results of 'phagograms', in a larger sample of participants are warranted.
Regardless of the final clinical outcome of the PhagoBurn study, it
showed that dedicated and realistic production and documentation requirements and treatment protocols are urgently needed.
Article 37 of the Declaration of Helsinki
The bottom line is that today there are no PTMPs on the EU market and that the pressure on clinicians to apply phage therapy in desperate cases is increasing, fuelled by an increasing promotion of phage therapy in the media (e.g. eulogising documentaries in prime time). However, even when confronted to serious public health threats, such as the 2011 E. coli O104:H4 outbreak in These phage-based products navigated easier commercial and regulatory paths than their human therapeutic counterparts. Even though it is expected that these non-human phage applications will pave the way for human applications, we wonder what will be the impact of this type of massive and unlimited environmental use of phages on the emergence of bacterial phage resistance (how fast will it emerge and will it persist or spread?) and on the composition of bacterial populations in the environment? Shouldn't we study this first? Shouldn't we learn from our (antibiotic) mistakes?
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Concluding remarks
Awaiting an adapted EU regulatory framework, Member States are exploring national solutions to make phages available to physicians, which are in desperate need of additional tools (in combination with other antibacterials) to fight multidrug resistant infections.
Politicians need to support these efforts, preferably at the European 
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